Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Blinklab Limited ( (AU:BB1) ) just unveiled an update.
BlinkLab Limited has announced leadership and board changes to enhance its operational alignment amid the pivotal FDA 510(k) trial for its autism diagnostic tool, BlinkLab Dx 1, which is projected to begin in early 2026. Co-founder Dr. Henk-Jan Boele, a seasoned leader in neuroscience and clinical implementation, assumes the role of Managing Director, reflecting the company’s readiness for growth and commercialization, supported by industry advancements such as successful pilot studies and global regulatory strategies. Non-Executive Director Ms. Jane Morgan steps down to focus on other commitments, leaving behind a legacy of critical contributions during BlinkLab’s listing and capital market activities.
More about Blinklab Limited
BlinkLab Limited is an Australian digital health company specializing in objective diagnostic technologies for neurodevelopmental conditions, such as autism and ADHD. The company focuses on advancing its innovative neurometric assessment tools, operating across multiple regions, including the U.S., Europe, and Australia, with key partnerships in leading clinical and research institutions.
Average Trading Volume: 353,871
Technical Sentiment Signal: Buy
Current Market Cap: A$109.5M
For a thorough assessment of BB1 stock, go to TipRanks’ Stock Analysis page.